Sign up
Quantellect · Analysts · Analyst Profile
Analyst Score Rank#162 of 589

Andrew Berens

Leerink Partners · Equity Research Analyst
EstablishedRating since 2020No new ratings since Nov 2025

Analyst rating accuracy & track record

Andrew Berens is an equity research analyst at Leerink Partners. Quantellect has scored 40 of their stock calls across 15 companies. Their picks beat their sector 53% of the time over the next 12 months, and their price targets were reached 46% of the time within a year.

Win % vs sector
53%
PT Hit % (12mo)
46%
Avg sector-excess
−0.0%
Scored calls
40
Tickers
15
Tier
Established

Track record

Quantellect has scored 40 of Andrew Berens's stock calls across 15 companies, dating back to 2020. Their rated stocks beat their own sector 53% of the time over the next 12 months. On a typical call, a Berens pick returned −0.0% more than its sector over the following year.

Of the scored calls, 40 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
COGTCogent Biosciences Inc
Buy$50.00Nov 2025−31.7%Miss
COGTCogent Biosciences Inc
Buy$50.00Nov 2025−31.7%Miss
IMRXImmuneering Corp
Buy$15.00Oct 2025−75.7%Miss
IMRXImmuneering Corp
Buy$15.00Oct 2025−75.7%Miss
EXELExelixis Inc
Buy$48.00Oct 2025+55.4%Hit
EXELExelixis Inc
Buy$48.00Oct 2025+55.4%Hit
BBOTBridgeBio Oncology Therapeutics, Inc.
Buy$25.00Sep 2025−78.7%Miss
CGEMCullinan Oncology LLC
Buy—Sep 2025+190.1%—
OKUROnKure Therapeutics, Inc.
Buy$33.00Aug 2025+18.7%Miss
OKUROnKure Therapeutics, Inc.
Buy$33.00Aug 2025+18.7%Miss
RLAYRelay Therapeutics Inc
Buy$12.00Aug 2025+458.8%Hit
RLAYRelay Therapeutics Inc
Buy$12.00Aug 2025+458.8%Hit
INCYIncyte Corporation
Buy$103.00Jul 2025+37.2%Hit
CELCCelcuity LLC
Buy$60.00Jul 2025+88.1%Hit
COGTCogent Biosciences Inc
Buy$18.00Jul 2025+285.7%Hit
NUVLNuvalent Inc
Buy$140.00Jun 2025+40.2%Miss
CMPXCompass Therapeutics Inc.
Buy$6.00Apr 2025+235.2%Hit
OKUROnKure Therapeutics, Inc.
Buy$33.00Dec 2024−86.5%Miss
ZYMEZymeworks Inc. Common Stock
Buy$25.00Nov 2024−0.1%Miss
ONCBeiGene, Ltd.
Buy$300.00Jan 2023−47.8%Miss
ONCBeiGene, Ltd.
Buy$236.00Dec 2022−10.7%Hit
AZNAstraZeneca PLC
Buy$79.00Nov 2022+4.9%Miss
AZNAstraZeneca PLC
Buy$78.00Nov 2022+4.9%Miss
ONCBeiGene, Ltd.
Buy$210.00Nov 2022+4.2%Hit
ONCBeiGene, Ltd.
Buy$200.00Oct 2022+7.9%Hit
Prev1
Go to

Andrew Berens: analyst track record FAQ

Is Andrew Berens a good stock analyst?

Yes, by track record. Andrew Berens ranks number 162 of 589 of the analysts Quantellect scores, with an Analyst Score of 50 out of 100. Past results do not guarantee future ones.

What is Andrew Berens's win rate?

Andrew Berens's win rate is 53%. Across 40 scored calls, their rated stocks beat their sector 53% of the time over the next 12 months. On a typical call they returned −0.0% more than the sector.

What stocks and sectors does Andrew Berens cover?

Andrew Berens covers 15 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Andrew Berens's price targets accurate?

Andrew Berens's price targets are reached within 12 months 46% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Andrew Berens's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Andrew Berens rank among Wall Street analysts?

Andrew Berens ranks number 162 of 589 by Analyst Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.